MARSEILLE, France–(BUSINESS WIRE)–Regulatory Information:
Innate Pharma SA (OTC:) (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Firm), right now introduced that the Firm will maintain a convention name on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to present an replace on enterprise progress throughout the first half of 2024.
Individuals throughout the name shall be:
- Hervé Brailly, Chief Govt Officer
- Sonia Quaratino, Govt Vice President, Chief Medical Officer
- Yannis Morel, Govt Vice President, Chief Working Officer
- Frédéric Lombard, Senior Vice President, Chief Monetary Officer
- Arvind Sood, Govt Vice President, President of US Operations
Particulars for the Digital Occasion
The reside webcast shall be accessible on the following hyperlink:
https://occasions.q4inc.com/attendee/127231232
Individuals can also be a part of by way of phone utilizing the next registration hyperlink: https://registrations.occasions/direct/Q4I953384196
This info may also be discovered on the Buyers part of the Innate Pharma web site, www.innate-pharma.com. A replay of the webcast shall be accessible on the Firm web site for 90 days following the occasion.
About Innate Pharma
Innate Pharma S.A. is a world, clinical-stage biotechnology firm growing immunotherapies for most cancers sufferers. Its revolutionary method goals to harness the innate immune system by way of therapeutic antibodies and its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
Innate’s portfolio contains lead proprietary program lacutamab, developed in superior type of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca (NASDAQ:) in non-small cell lung most cancers, in addition to ANKET ® multi-specific NK cell engagers to handle a number of tumor sorts.
Innate Pharma is a trusted accomplice to biopharmaceutical corporations similar to Sanofi (NASDAQ:) and AstraZeneca, in addition to main analysis establishments, to speed up innovation, analysis and improvement for the advantage of sufferers.
Headquartered in Marseille, France with a US workplace in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq within the US.
Study extra about Innate Pharma at www.innate-pharma.com and observe us on LinkedIn and X.
Details about Innate Pharma shares
|
ISIN code |
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking info and threat elements
This press launch incorporates sure forward-looking statements, together with these throughout the that means of the Non-public Securities Litigation Reform Act of 1995. The usage of sure phrases, together with imagine, potential, anticipate and can and related expressions, is meant to establish forward-looking statements. Though the corporate believes its expectations are primarily based on cheap assumptions, these forward-looking statements are topic to quite a few dangers and uncertainties, which may trigger precise outcomes to vary materially from these anticipated. These dangers and uncertainties embody, amongst different issues, the uncertainties inherent in analysis and improvement, together with associated to security, development of and outcomes from its ongoing and deliberate medical trials and preclinical research, evaluation and approvals by regulatory authorities of its product candidates, the Firm’s commercialization efforts and the Firm’s continued potential to boost capital to fund its improvement. For a further dialogue of dangers and uncertainties which may trigger the corporate’s precise outcomes, monetary situation, efficiency or achievements to vary from these contained within the forward-looking statements, please consult with the Danger Elements (Facteurs de Risque”) part of the Common Registration Doc filed with the French Monetary Markets Authority (AMF), which is obtainable on the AMF web site http://www.amf-france.org or on Innate Pharma’s web site www.innate-pharma.com, and public filings and studies filed with the U.S. Securities and Alternate Fee (SEC), together with the Firm’s Annual Report on Kind 20-F for the yr ended December 31, 2023, and subsequent filings and studies filed with the AMF or SEC, or in any other case made public, by the Firm.
This press launch and the data contained herein don’t represent a suggestion to promote or a solicitation of a suggestion to purchase or subscribe to shares in Innate Pharma in any nation.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240904420893/en/
For extra info, please contact:
Buyers
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Supply: Innate Pharma SA
